News - Lupus Foundation of America
Dec 19, 2024 · The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy.
New Research Finds Cells May Cause Systemic Lupus …
Jul 11, 2024 · In a new study, researchers discovered a mechanism that may contribute to lupus development and a possible new approach to reverse or cure the disease. Scientists examined the blood of 19 people with SLE and compared it to those of healthy individuals.
Latest Discoveries in Lupus Research Highlighted at ACR’s 2023 ...
Nov 14, 2023 · The American College of Rheumatology’s (ACR’s) 2023 annual meeting is well underway and significant advances as well as new discoveries in lupus research have taken center stage.
Lupus Research News from ACR’s 2022 Scientific Meeting
Nov 15, 2022 · From November 10 – 14, world experts in lupus research, treatment, care and advocacy convened to share the latest news and signal future directions for the field. The Lupus Foundation of America (LFA) was a proud supporter of several studies presented at this year’s ACR Convergence.
New Investigational Drug for Refractory Systemic Lupus …
Dec 19, 2023 · The U.S. Food and Drug Administration has cleared (when a clinical study sponsor receives approval to administer an investigational drug or biological product to humans) an application for a new investigational therapy, FasTCAR-T GC012F, for treatment of refractory systemic lupus erythematosus.
Deucravacitinib Outperforms Other Biologic Therapies for …
Dec 23, 2024 · In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus disease than two other commonly used therapies, anifrolumab and litifilimab.
ACR 2024 - Lupus Foundation of America
Nov 18, 2024 · The summary guideline focuses on preserving kidney function and minimizing life-threatening outcomes from lupus nephritis (LN), while ensuring collaborative care and shared decision making with patients and also minimizing medication-related toxicities.
Potential Lupus Drug Deucravacitinib Moves Onto Phase 3 Clinical …
Jun 2, 2022 · The 48-week study showed that deucravacitinib was safe, well tolerated and effective for people with lupus. Study participants who received the oral drug saw greater improvements in several measures of disease activity, including overall activity and organ-specific activity, compared to the placebo group.
High-Dose BI655064 Shows Promising Results in Improving Renal …
Dec 13, 2024 · In a new study, researchers evaluated the treatment effects of BI655064, an anti-CD40 monoclonal antibody, as an add-on therapy for people living with lupus nephritis (LN, lupus related kidney disease).
Fate Therapeutics Announces Promising Initial Data from FT819 …
Dec 12, 2024 · Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with moderate-to-severe systemic lupus erythematosus (SLE). The ongoing trial is evaluating safety, pharmacokinetics, and …